Table 2.
Expression of LL-37 peptide in monocyte-derived macrophages from healthy adults before and after supplementation
|
LL-37 level in ICF (ng/million cells) |
||||
|---|---|---|---|---|
| Day-0 | Day-4 | Day-8 | ||
| Group-I |
MDM |
0.52 ± 0.06 |
0.72 ± 0.28 |
0.68 ± 0.19 |
| Group-II |
MDM |
0.33 ± 0.02 |
1.22 ± 0.49a 1 |
0.36 ± 0.05 |
| Group-III |
MDM |
0.28 ± 0.00 |
0.27 ± 0.02 |
0.27 ± 0.02 |
| Group-IV |
MDM |
0.15 ± 0.02 |
0.13 ± 0.02 |
0.16 ± 0.02 |
| Group-V | MDM | 0.21 ± 0.08 | 0.20 ± 0.05 | 0.23 ± 0.09 |
Note: Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. Data expressed as Mean ± Standard Deviation. One Way Analysis of Variance (ANOVA) method was used for statistical analysis. Kruskal-Wallis ANOVA on Ranks was performed when the data was not normally distributed; analysis of Co-variance was performed when significant difference was found at entry level. Differences are significant, when p < 0.05. Difference between, aday-4 and day-0 within Group-II (p = 0.02); 1Group-II and -III within day-4 (p = 0.034). ICF, Intracellular fluid; PB, Phenylbutyrate; MDM, Monocyte-derived macrophages; b.d., Twice daily; o.d., Once daily.